South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Freenome is raising $269,999,879.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gabriel Otte played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Freenome

At Freenome, we’re connecting people with next-generation blood tests for early cancer detection powered by our multiomics platform. Freenome is a biotechnology company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective.

To learn more about Freenome, visit http://www.freenome.com/

Contact:
Gabriel Otte, Chief Executive Officer
650-446-6630
gabriel-otte@freenome.com
https://www.linkedin.com/in/gabrielotte/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved